FDA ‘blind spot’ grants reproduction of drugs in shortages – creating $1bn market of unbranded weight-loss drugsAn obscure federal statute is allowing US pharmacies to flood the market with unvetted knockoffs of Ozempic, the pricey weight-loss drug that is reducing and transforming the weight and silhouettes of millions of Americans.According to a Bloomberg investigation published Monday, a “blind spot” in Food and Drug Administration (FDA) regulations that allows pharmacies and compounders to reproduce drugs that are in short supply has helped to create a market of unbranded weight-loss drugs worth $1bn annually. Continue reading…
Source link : https://www.theguardian.com/us-news/article/2024/jul/22/ozempic-knockoffs-weight-loss-drugs-fda
Author : Edward Helmore
Publish date : 2024-07-22 20:07:15
Copyright for syndicated content belongs to the linked Source.
